BioCardia, Inc. (BCDA)
NASDAQ: BCDA · Real-Time Price · USD
1.930
-0.070 (-3.50%)
At close: Apr 10, 2025, 4:00 PM
1.965
+0.035 (1.79%)
After-hours: Apr 10, 2025, 7:50 PM EDT
BioCardia Revenue
In the year 2024, BioCardia had annual revenue of $58.00K, down -87.84%.
Revenue (ttm)
$58.00K
Revenue Growth
-87.84%
P/S Ratio
91.30
Revenue / Employee
$2,900
Employees
20
Market Cap
9.03M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 58.00K | -419.00K | -87.84% |
Dec 31, 2023 | 477.00K | -875.00K | -64.72% |
Dec 31, 2022 | 1.35M | 337.00K | 33.20% |
Dec 31, 2021 | 1.02M | 870.00K | 600.00% |
Dec 31, 2020 | 145.00K | -565.00K | -79.58% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
BCDA News
- 10 days ago - BioCardia, Inc. (BCDA) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 10 days ago - BioCardia's Conference Call Today, Monday, March 31, 2025 to be Held at 4:30PM EDT Time Today - GlobeNewsWire
- 15 days ago - BioCardia Reports 2024 Business Highlights and Financial Results - GlobeNewsWire
- 20 days ago - BioCardia to Host 2024 Financial Results and Corporate Update Conference Call on March 31, 2025 - GlobeNewsWire
- 4 weeks ago - BioCardia Announces Japanese Patent for Helix™ Biotherapeutic Delivery System - GlobeNewsWire
- 6 weeks ago - BioCardia Announces Primary Outcome Measures Data Freeze in CardiAMP Heart Failure Trial for Presentation at the American College of Cardiology 2025 Scientific Sessions - GlobeNewsWire
- 2 months ago - BioCardia Reports Completion of Low Dose Cohort Enrollment for CardiALLO Phase I/II Clinical Trial of BCDA-03 Allogeneic Mesenchymal Stem Cells to Treat Ischemic Heart Failure of Reduced Ejection Fraction (HFrEF) - GlobeNewsWire
- 2 months ago - BioCardia Announces Late Breaking Clinical Trial Presentation on CardiAMP Heart Failure Trial at the American College of Cardiology 2025 Scientific Sessions - GlobeNewsWire